MBOT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MBOT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Microbot Medical's annualized Net Income for the quarter that ended in Dec. 2024 was $-13.57 Mil. Microbot Medical's average total tangible assets for the quarter that ended in Dec. 2024 was $5.62 Mil. Therefore, Microbot Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -241.44%.
The historical rank and industry rank for Microbot Medical's Return-on-Tangible-Asset or its related term are showing as below:
During the past 13 years, Microbot Medical's highest Return-on-Tangible-Asset was -5.65%. The lowest was -495.92%. And the median was -92.49%.
The historical data trend for Microbot Medical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Return-on-Tangible-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
-28.92 | -52.56 | -100.12 | -120.24 | -159.40 |
Microbot Medical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Return-on-Tangible-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-146.57 | -120.86 | -133.23 | -203.45 | -241.44 |
For the Medical Instruments & Supplies subindustry, Microbot Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Microbot Medical's Return-on-Tangible-Asset falls into.
Microbot Medical's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Dec. 2024 ) | (A: Dec. 2023 ) | (A: Dec. 2024 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Dec. 2024 ) | (A: Dec. 2023 ) | (A: Dec. 2024 ) | |||||
= | -11.443 | / | ( (8.327 | + | 6.031) | / 2 ) | |
= | -11.443 | / | 7.179 | ||||
= | -159.40 % |
Microbot Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Dec. 2024 ) | (Q: Sep. 2024 ) | (Q: Dec. 2024 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Dec. 2024 ) | (Q: Sep. 2024 ) | (Q: Dec. 2024 ) | |||||
= | -13.568 | / | ( (5.208 | + | 6.031) | / 2 ) | |
= | -13.568 | / | 5.6195 | ||||
= | -241.44 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2024) net income data.
Microbot Medical (NAS:MBOT) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Microbot Medical's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Rachel Vaknin | officer: Chief Financial Officer | DROR 3/10, ZICHRON YAAKOV L3 3090216 |
Simon Sharon | officer: General Manager & CTO | 8 HAMADA STREET, ZICHRON YAACOV L3 3090708 |
Yoseph Bornstein | director, 10 percent owner | 16 IRUS STREET, ROSH HA'AYIN L3 4858022 |
Tal Baruch Wenderow | director | 1149, BEACON STREET, NEWTON MA 02461 |
Eyal Morag | officer: Chief Medical Officer | BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303 |
Aileen Ptucha Stockburger | director | 26 WELLINGTON CT, BELLE MEADE NJ 08502 |
Harel Gadot | director, 10 percent owner, officer: Chairman and CEO | 5 VILLAGE LANE, HINGHAM MA 02043 |
Joseph Mona | 10 percent owner | 808 HAMPTON ST, COLUMBIA SC 29201 |
Prattipati Laxminarain | director | 3 HEWINS FARM ROAD, WELLESLEY MA 02481 |
Yoav Zvi Waizer | director | 8 HAVERED STREET, RAANANA L3 4352308 |
Moshe Shoham | director | 22 BEDOLACH STREET, HOSHAYA L3 1791500 |
Leon Lewkowicz | 10 percent owner | GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458 |
Martin J. Madden | director | C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043 |
Yehezkel Himelfarb | officer: General Manager & COO | 32 BEN YOSEF STREET, TEL-AVIV L3 6912530 |
Sandra Berkson | 10 percent owner | C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020 |
From GuruFocus
By Marketwired • 02-10-2025
By Marketwired • 04-09-2025
By Marketwired • 02-25-2025
By Marketwired • 01-13-2025
By Marketwired • 04-01-2025
By Marketwired • 02-12-2025
By GuruFocus News • 04-09-2025
By Marketwired • 01-10-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.